S. K. Kumar, S. V. Rajkumar, and A. Dispenzieri, Improved survival in multiple myeloma and the impact of novel therapies, Blood, vol.111, issue.5, pp.2516-2520, 2008.

P. Moreau and C. Touzeau, Multiple myeloma: from front-line to relapsed therapies, Am. Soc. Clin. Oncol. Educ. Book, vol.35, pp.504-511, 2015.

P. G. Richardson, P. Sonneveld, and M. W. Schuster, Bortezomib or high-dose dexamethasone for relapsed multiple myeloma, N. Engl. J. Med, vol.352, issue.24, pp.2487-2498, 2005.

P. Moreau, H. Pylypenko, and S. Grosicki, Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, Phase III, noninferiority study, Lancet Oncol, vol.12, issue.5, pp.431-440, 2011.

M. A. Dimopoulos, P. Moreau, and A. Palumbo, Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomized, Phase III, open-label, multicenter study, Lancet Oncol, vol.17, issue.1, pp.27-38, 2016.

A. K. Stewart, S. V. Rajkumar, and M. A. Dimopoulos, lenalidomide and dexamethasone for relapsed multiple myeloma, N. Engl. J. Med, vol.372, issue.2, pp.142-152, 2015.

P. Hari, M. Mateos, and R. Abonour, Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes, Leukemia, vol.31, issue.12, pp.2630-2641, 2017.

E. Kupperman, E. C. Lee, and Y. Cao, Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer, Cancer Res, vol.70, issue.5, pp.1970-1980, 2010.

P. Moreau, T. Masszi, and N. Grzasko, Oral ixazomib, lenalidomide and dexamethasone for multiple myeloma, N. Engl. J. Med, vol.374, issue.17, pp.1621-1634, 2016.

D. Chauhan, Z. Tian, and B. Zhou, In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells, Clin. Cancer Res, vol.17, issue.16, pp.5311-5321, 2011.

P. G. Richardson, R. Baz, and M. Wang, Phase I study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients, Blood, vol.124, issue.7, pp.1038-1046, 2014.

S. K. Kumar, W. I. Bensinger, and T. M. Zimmerman, Phase I study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma, Blood, vol.124, issue.7, pp.1047-1055, 2014.

N. Gupta, P. M. Diderichsen, and M. J. Hanley, Population pharmacokinetic analysis of ixazomib, an oral proteasome inhibitor, including data from the Phase III TOURMALINE-MM1 study to inform labeling, Clin. Pharmacokinet, vol.56, issue.11, pp.1355-1368, 2017.

, Millennium Pharmaceuticals Inc. Ninlaro (ixazomib) capsules, for oral use. United States prescribing information, 2015.

Z. Tian, J. Zhao, and Y. Tai, Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells, Blood, vol.120, pp.3958-3967, 2012.

S. Arastu-kapur, J. L. Anderl, and M. Kraus, Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events, Clin. Cancer Res, vol.17, issue.9, pp.2734-2743, 2011.

S. K. Kumar, B. Laplant, and V. Roy, Phase II trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib, Blood Cancer J, vol.5, p.338, 2015.

S. K. Kumar, B. R. Laplant, and C. B. Reeder, Randomized Phase II trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib, Blood, vol.128, issue.20, pp.2415-2422, 2016.

M. Attal, V. Lauwers-cances, and C. Hulin, bortezomib and dexamethasone with transplantation for myeloma, N. Engl. J. Med, vol.376, issue.14, pp.1311-1320, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01557406

S. K. Kumar, J. G. Berdeja, and R. Niesvizky, Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label Phase I/II study, Lancet Oncol, vol.15, issue.13, pp.1503-1512, 2014.

M. Mateos, T. Masszi, and N. Grzasko, Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1, Haematologica, vol.102, issue.10, pp.1767-1775, 2017.

P. G. Richardson, S. Kumar, and J. P. Laubach, New developments in the management of relapsed/refractory multiple myeloma-the role of ixazomib, J. Blood Med, vol.8, pp.107-121, 2017.

S. Kumar, P. Moreau, and H. P. , Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma, Br. J. Haematol, vol.178, issue.4, pp.571-582, 2017.

H. Jouni, M. C. Aubry, and M. Q. Lacy, Ixazomib cardiotoxicity: a possible class effect of proteasome inhibitors, Am. J. Hematol, vol.92, issue.2, pp.220-221, 2017.

H. Avet-loiseau, N. J. Bahlis, and W. Chng, Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients, Blood, vol.130, issue.24, pp.2610-2618, 2017.

H. Avet-loiseau, R. Fonseca, and D. Siegel, Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma, Blood, vol.128, issue.9, pp.1174-1180, 2016.

N. Gupta, M. J. Hanley, and R. D. Harvey, A pharmacokinetics and safety Phase I/Ib study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis, Br. J. Haematol, vol.174, issue.5, pp.748-759, 2016.

L. Benboubker, M. A. Dimopoulos, and A. Dispenzieri, Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma, N. Engl. J. Med, vol.371, issue.10, pp.906-917, 2014.

S. Zweegman, B. Van-der-holt, F. Schjesvold, and N. Abildgaard, Ixazomib-thalidomide-low dose dexamethasone (ITd) induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation, of Hematology 59th Annual Meeting and Exposition, pp.9-12, 2017.

P. Moreau, C. Hulin, and D. Caillot, Ixazomib-lenalidomide-dexamethasone (IRd) combination before and after autologous stem cell transplantation (ASCT) followed by ixazomib maintenance in patients with newly diagnosed multiple myeloma (NDMM): a Phase II study from the Intergroupe Francophone Du MyéLome (IFM), Blood, vol.128, issue.22, pp.674-674, 2016.

M. Dimopoulos, J. Laubach, M. Gutierrez, and P. G. Richardson, Efficacy and safety of long-term ixazomib maintenance therapy in patients (Pts) with newly diagnosed multiple myeloma (NDMM) not undergoing transplant: an integrated analysis of four Phase I/II studies, of Hematology 59th Annual Meeting and Exposition, pp.9-12, 2017.

M. Berenson, A. Cohen, and T. Spektor, Replacement of ixazomib for relapsed/refractory multiple myeloma patients refractory to a bortezomib or carfilzomib-containing combination therapy, J. Clin. Oncol, issue.15, p.8013, 2017.